also observed AEs such as scoliosis, hypothyroidism, and changes in carbohydrate metabolism with GH treatment in pediatric patients with ISS based on a dosing range of 0.22–0.37 mg/kg/week (28). This evidence concerns the gene GH1 and hypothyroidism.